Effector Therapeutics Inc
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and a… Read more
Effector Therapeutics Inc (EFTR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2024: -8.800x
Based on the latest financial reports, Effector Therapeutics Inc (EFTR) has a cash flow conversion efficiency ratio of -8.800x as of March 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.28 Million) by net assets ($827.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Effector Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2019–2023)
This chart illustrates how Effector Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Effector Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Effector Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hunter Creek Mining Co
PINK:HTRC
|
N/A |
|
DALIAN PORT (PDA)-H
MU:D7P
|
N/A |
|
MAJESTIC GOLD
MU:MJT
|
0.063x |
|
Pakistan International Container Terminal Ltd
KAR:PICT
|
-0.023x |
|
Caledonian Trust PLC
LSE:CNN
|
0.011x |
|
Ghani Chemical Industries Ltd
KAR:GCIL
|
N/A |
|
RAIZ4F
SA:RAIZ4F
|
N/A |
|
Narf Industries PLC
LSE:NARF
|
0.406x |
Annual Cash Flow Conversion Efficiency for Effector Therapeutics Inc (2019–2023)
The table below shows the annual cash flow conversion efficiency of Effector Therapeutics Inc from 2019 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-5.79 Million | $-29.55 Million | 5.099x | +176.71% |
| 2022-12-31 | $3.90 Million | $-25.90 Million | -6.648x | -361.66% |
| 2021-12-31 | $17.28 Million | $-24.89 Million | -1.440x | -1276.40% |
| 2020-12-31 | $-132.25 Million | $13.84 Million | -0.105x | -105.25% |
| 2019-12-31 | $-13.84 Million | $-27.60 Million | 1.994x | -- |